Multidisciplinary management of childhood sarcoma: time to expand

References

• Dantonello TM, Int-Veen C, Harms D et al. Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults. J. Clin. Oncol.27(9), 1446–1455 (2009).
   PubMed Web of Science ®Google Scholar
• Stevens MC, Rey A, Bouvet N et al. Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology – SIOP Malignant Mesenchymal Tumor 89. J. Clin. Oncol.23(12), 2618–2628 (2005).
   PubMed Web of Science ®Google Scholar
• Stevens MC. Philosophy of treatment and the role of chemotherapy in paediatric soft tissue sarcomas. Eur. J. Cancer Suppl.1, 237–247 (2003).
   Google Scholar
• Carli M, Colombatti R, Oberlin O et al. European intergroup studies (MMT4–89 and MMT4–91) on childhood metastatic rhabdomyosarcoma: final results and analysis of prognostic factors. J. Clin. Oncol.22(23), 4787–4794 (2004).
   PubMed Web of Science ®Google Scholar
• McDowell HP, Foot AB, Ellershaw C et al. Outcomes in paediatric metastatic rhabdomyosarcoma: results of the International Society of Paediatric Oncology (SIOP) study MMT-98. Eur. J. Cancer46(9), 1588–1595 (2010).
   PubMed Web of Science ®Google Scholar
• Williamson D, Missiaglia E, de Reynies A et al. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J. Clin. Oncol.28(13), 2151–2158 (2010).
   PubMed Web of Science ®Google Scholar
• Charytonowicz E, Cordon-Cardo C, Matushansky I, Ziman M. Alveolar rhabdomyosarcoma: is the cell of origin a mesenchymal stem cell? Cancer Lett.279(2), 126–136 (2009).
   PubMed Web of Science ®Google Scholar
• Ayyanathan K, Fredericks WJ, Berking C et al. Hormone-dependent tumor regression in vivo by an inducible transcriptional repressor directed at the PAX3–FKHR oncogene. Cancer Res.60(20), 5803–5814 (2000).
   PubMedGoogle Scholar
• Bernasconi M, Remppis A, Fredericks WJ, Rauscher FJ 3rd, Schafer BW. Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins. Proc. Natl Acad. Sci. USA93(23), 13164–13169 (1996).
   PubMed Web of Science ®Google Scholar
• Kikuchi K, Tsuchiya K, Otabe O et al. Effects of PAX3-FKHR on malignant phenotypes in alveolar rhabdomyosarcoma. Biochem. Biophys. Res. Commun.365(3), 568–574 (2008).
   PubMed Web of Science ®Google Scholar
• Hecker RM, Amstutz RA, Wachtel M et al. p21 downregulation is an important component of PAX3/FKHR oncogenicity and its reactivation by HDAC inhibitors enhances combination treatment. Oncogene29(27), 3942–3952 (2010).
   PubMedGoogle Scholar
• Denayer E, Devriendt K, de Ravel T et al. Tumor spectrum in children with Noonan syndrome and SOS1 or RAF1 mutations. Genes Chromosomes Cancer49(3), 242–252 (2009).
   Google Scholar
• Martinelli S, McDowell HP, Vigne SD et al. RAS signaling dysregulation in human embryonal rhabdomyosarcoma. Genes Chromosomes Cancer48(11), 975–982 (2009).
   PubMedGoogle Scholar
• Zibat A, Uhmann A, Nitzki F et al. Time-point and dosage of gene inactivation determine the tumor spectrum in conditional Ptch knockouts. Carcinogenesis30(6), 918–926 (2009).
   PubMed Web of Science ®Google Scholar
• Anderson J, Gordon A, McManus A, Shipley J, Pritchard-Jones K. Disruption of imprinted genes at chromosome region 11p15.5 in paediatric rhabdomyosarcoma. Neoplasia1(4), 340–348 (1999).
   PubMedGoogle Scholar
• Cao L, Yu Y, Darko I et al. Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res.68(19), 8039–8048 (2008).
   PubMed Web of Science ®Google Scholar
• Wachtel M, Runge T, Leuschner I et al. Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry. J. Clin. Oncol.24(5), 816–822 (2006).
   PubMed Web of Science ®Google Scholar
• Ganti R, Skapek SX, Zhang J et al. Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma. Mod. Pathol.19(9), 1213–1220 (2006).
   PubMed Web of Science ®Google Scholar
• Bennicelli JL, Barr FG. Chromosomal translocations and sarcomas. Curr. Opin. Oncol.14(4), 412–419 (2002).
   PubMed Web of Science ®Google Scholar
• Mercado GE, Xia SJ, Zhang C et al. Identification of PAX3–FKHR-regulated genes differentially expressed between alveolar and embryonal rhabdomyosarcoma: focus on MYCN as a biologically relevant target. Genes Chromosomes Cancer47(6), 510–520 (2008).
   PubMed Web of Science ®Google Scholar
• Taylor JG, Cheuk AT, Tsang PS et al. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J. Clin. Invest.119(11), 3395–3407 (2009).
   PubMed Web of Science ®Google Scholar
• Schaaf G, Hamdi M, Zwijnenburg D et al. Silencing of SPRY1 triggers complete regression of rhabdomyosarcoma tumors carrying a mutated RAS gene. Cancer Res.70(2), 762–771 (2010).
   PubMed Web of Science ®Google Scholar
• Oesch S, Walter D, Wachtel M et al. Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma. Mol. Cancer Ther.8(7), 1838–1845 (2009).
   PubMed Web of Science ®Google Scholar
• Davicioni E, Finckenstein FG, Shahbazian V et al. Identification of a PAX–FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res.66(14), 6936–6946 (2006).
   PubMed Web of Science ®Google Scholar
• Taulli R, Scuoppo C, Bersani F et al. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. Cancer Res.66(9), 4742–4749 (2006).
   PubMed Web of Science ®Google Scholar